A Phase 2 interventional study of Empagliflozin (SGLT2i) and dapagliflozin in No Reflow Phenomenon, Reperfusion Injuries, Myocardial and Myocardial Infarction, sponsored by Al-Azhar University. Not yet recruiting at 4 sites in Egypt. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Al-Azhar University · Phase 2, Interventional, and Treatment
Study Background \& Purpose:
The no-reflow phenomenon is a significant complication occurring in patients with acute myocardial infarction who undergo percutaneous coronary intervention (PCI). It leads to poor myocardial perfusion despite successful opening of the culprit coronary artery. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have demonstrated cardioprotective mechanisms beyond glucose control.
Objective:
This randomized controlled trial aims to evaluate the effectiveness and safety of administering SGLT2 inhibitors as adjunctive therapy in reducing the incidence of the no-reflow phenomenon in patients with myocardial infarction undergoing PCI.
Study Plan:
Eligible patients presenting with myocardial infarction scheduled for PCI will be randomized into three groups: one group receiving standard pharmacological care plus Empagliflozin therapy, second group receiving standard pharmacological care plus dapagliflozin therapy, and the control group receiving standard pharmacological care alone. Patients will be monitored during and after the procedure to evaluate coronary blood flow and incidence of no reflow phenomenon.
25 studies on the registry are indexed under No-Reflow Phenomenon; 9 are open to participants now.
This study's planned enrollment of 100 is below the median of 201 across 17 interventional studies indexed under No-Reflow Phenomenon.
Browse No-Reflow Phenomenon studies →Al-Azhar University is the lead sponsor of 527 studies on the registry; 171 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients meeting any of the following criteria will be excluded:
For women of childbearing age:
Patients with myocardial infarction undergoing PCI will receive standard of care pharmacological Treatment alone.
Drug: Standard medical treatment
Patients with myocardial infarction undergoing PCI will receive standard of care pharmacological Treatment in addition to empagliflozin orally as a single oral dose before PCI, followed by empagliflozin orally once daily for three days.
Drug: Empagliflozin (SGLT2i) · Drug: Standard medical treatment
Patients with myocardial infarction undergoing PCI will receive standard of care pharmacological Treatment in addition to Dapagliflozin orally as a single oral dose before PCI, followed by empagliflozin orally once daily for three days.
Drug: dapagliflozin · Drug: Standard medical treatment
Patients will receive standard guideline-directed treatment in accordance with current clinical guidelines in addition to empagliflozin orally as a single oral dose before PCI, followed by empagliflozin orally once daily for three days.
Patients will receive standard guideline-directed treatment in accordance with current clinical guidelines in addition to dapagliflozin orally as a single oral dose before PCI, followed by dapagliflozin orally once daily for three days.
Patients will receive standard guideline-directed treatment in accordance with current clinical guidelines and undergo percutaneous coronary intervention without receiving any study medication.
Incidence of angiographic no-reflow/impaired myocardial reperfusion
Angiographic no-reflow/impaired myocardial reperfusion, defined as TIMI flow grade.
Time frame: Periprocedural(At completion of PCI)
Incidence Contrast induced-Acute Kidney injury(CI-AKI)
Contrast induced-Acute Kidney injury(CI-AKI) measured by serum creatinine
Time frame: up to 72 hours Post PCI
Plan to share: No
Start is estimated for Jan 2027; primary completion for Jun 2027, 5 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Empagliflozin · Dapagliflozin